NCT07540390 2026-04-22
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
22 trialsNCT07545213 2026-04-22
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT07538258 2026-04-20
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07538271 2026-04-20
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07501169 2026-04-13
STAR-01
Sichuan University
Phase 2 Not yet recruiting
NCT07520760 2026-04-09
MBC-EA
Sun Yat-sen University
Phase 2 Recruiting
NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
NCT04877821 2026-04-02
NeoSACT
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT07470840 2026-03-24
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07489300 2026-03-24
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07320963 2026-03-20
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07455019 2026-03-06
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07443397 2026-03-02
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT07193186 2026-02-27
Anlotinib and Benmelstobart in DTC
Fudan University
Phase 2 Not yet recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT07396454 2026-02-09
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07398326 2026-02-09
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT06662006 2026-02-06
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeĀ±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05685550 2026-02-05
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting